Hal Barron To Depart GSK To Head Up New Biotech

Tony Wood To Take Over

As Barron departs for new rejuvenation-focused biotech Altos Labs, GSK will be under pressure to ensure its R&D can continue to produce green shoots.

Hal Barron, Chief Scientific Officer and President R&D at GSK
Hal Barron will be CEO of the new rejuvenation-focused biotech Altos Labs • Source: GSK

Hal Barron is to leave his role as GlaxoSmithKline’s R&D head to become CEO of Altos Labs, a new San Francisco-based biotech focused on the biology of cellular rejuvenation.

Barron is leaving just four years after being hired to turn around GSK’s research operations, and will be succeeded as...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip